The Bile Acid Receptor TGR5 Does Not Interact with β-Arrestins or Traffic to Endosomes but Transmits Sustained Signals from Plasma Membrane Rafts*

Dane D. Jensen†, Cody B. Godfrey†, Christian Niklas‡, Meritxell Canals‡, Martina Kocan‡, Daniel P. Poole†, Jane E. Murphy†, Farzad Alemi†, Graeme S. Cottrell‡, Christoph Korbmacher‡, Nevin A. Lambert∗∗, Nigel W. Bunnett†, and Carlos U. Corvera‡

From the †Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia, the ‡Department of Surgery and the Veterans Affairs Medical Center, University of California, San Francisco, California 94143, the ¶Institut für Zelluläre Physiologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany, the Department of Pharmacy and Pharmacology, Reading School of Pharmacy, Reading University, Whiteknights, Reading RG6 6UB, United Kingdom, and the **Department of Pharmacology and Toxicology, Georgia Regents University, Augusta, Georgia 30912

Background: The TGR5 bile acid receptor controls energy balance, inflammation, and digestion, but TGR5 signaling is poorly understood.

Results: TGR5 does not interact with β-arrestins, internalize, or desensitize, but signals from plasma membrane rafts.

Conclusion: TGR5 transmits sustained signals close to the cell surface.

Significance: Understanding TGR5 signaling will facilitate design of TGR5 agonists for metabolic, inflammatory, and digestive disorders.

TGR5 is a G protein-coupled receptor that mediates bile acid (BA) effects on energy balance, inflammation, digestion, and sensation. The mechanisms and spatiotemporal control of TGR5 signaling are poorly understood. We investigated TGR5 signaling and trafficking in transfected HEK293 cells and colonocytes (NCM460) that endogenously express TGR5. BAs (deoxycholic acid (DCA), tauroli cholthic acid) and the selective agonists oleanolic acid and 3-(2-chlorophenyl)-N-(4-chlorophenyl)-N, 5-dimethylisoxazole-4-carboxamide stimulated cAMP formation but did not induce TGR5 endocytosis or recruitment of β-arrestins, as assessed by confocal microscopy. DCA, tauroli cholthic acid, and oleanolic acid did not stimulate TGR5 association with β-arrestin 1/2 or G protein-coupled receptor kinase (GRK) 2/5/6, as determined by bioluminescence resonance energy transfer analysis revealed TGR5 and EGFR interactions that were blocked by disruption of lipid rafts. DCA stimulated TGR5 redistribution to plasma membrane microdomains, as localized by immunogold electron microscopy. Thus, TGR5 does not interact with β-arrestins, desensitize, or traffic to endosomes. TGR5 signals from plasma membrane rafts that facilitate EGFR interaction and transactivation. An understanding of the spatiotemporal control of TGR5 signaling provides insights into the actions of BAs and therapeutic TGR5 agonists/antagonists.

During feeding, the presence of lipids in the small intestine stimulates the release of cholecystokinin, a hormone that induces contraction of the gall bladder and secretion of bile into the intestine. Bile acids (BAs) are a major component of bile. The two primary bile acids in humans, chenodeoxycholic acid and cholic acid, facilitate the emulsification and absorption of dietary fats and the lipid-soluble vitamins A, D, E, and K (1, 2). The bulk of the primary BAs are absorbed in the ileum by the sodium bile acid transporter. Primary BAs that escape ileal absorption pass into the colon and are converted by bacterial enzymes to secondary BAs, including deoxycholic acid (DCA), lithocholic acid, tauroli cholthic acid (TLCA), and ursodeoxycholic acid, which are absorbed passively. Absorbed BAs enter

* This work was supported, in whole or in part, by National Institutes of Health Grants P30-DK026743 from NIDDK (to C. U. C.). This work was also supported by the Northern California Institute for Research and Education, the Veterans Health Administration, National Health and Medical Research Council (NHMRC) Grants 63303 and 103188, and Monash University (to N. W. B.); by NHMRC Grant 454858 (to D. P. P.); and by British Heart Foundation Grant FS/08/017/25027 (to G. S. C.).

† To whom correspondence may be addressed: Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC 3052, Australia. Tel.: 61-3-9903-9136; Fax: 61-3-9903-9581; E-mail: carlos.corvera@ucsfmedctr.org.

‡ To whom correspondence may be addressed: Department of Surgery, University of California, San Francisco, Veterans Affairs Medical Center, Surgical Service (112), 4150 Clement St., San Francisco, CA 94121. Tel.: 415-221-4180 (ext. 4019); E-mail: carlos.corvera@ucsfmedctr.org.

§ The abbreviations used are: BA, bile acid; DCA, deoxycholic acid; TLCA, tauroli cholthic acid; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; EGFR, epidermal growth factor receptor; OA, oleanolic acid; CCDC, 3-(2-chlorophenyl)-N-(4-chlorophenyl)-N, 5-dimethylisoxazole-4-carboxamide; PAR, protease-activated receptor; BRET, bioluminescence resonance energy transfer; HBSS, Hank’s balanced salt solution; CAMYEL, cAMP sensor using YFP-Epc-RLuc; YFP, yellow fluorescent protein.

‡¶ Martina Kocan, Christoph Korbmacher, Meritxell Canals, Cody B. Godfrey, Carlos U. Corvera, Christian Niklas, Nigel W. Bunnett, Nevin A. Lambert, and Carlos U. Corvera.

§2 Christian Niklas, Christoph Korbmacher, Meritxell Canals, Cody B. Godfrey, Carlos U. Corvera, Christian Niklas, Christoph Korbmacher, Meritxell Canals, Cody B. Godfrey, Carlos U. Corvera, Christian Niklas, Christoph Korbmacher, Meritxell Canals, Cody B. Godfrey, Carlos U. Corvera.
the portal vein and recycle to the liver via the enterohepatic circulation. Because bile is secreted into the intestine episodically, the circulating levels of BAs wax and wane during feeding and fasting, similar to the levels of gut hormones, and BAs have hormone-like effects on many cell types (1, 3, 4). Moreover, the synthesis, secretion, absorption, and metabolism of BAs are under tight physiological control, and defects in these processes lead to abnormal circulating and intestinal concentrations of BAs, which can cause disease (1, 3, 4).

BAs exert their hormone-like effects by activating receptors in the nucleus or at the plasma membrane (1, 3, 4). Nuclear BAs receptors include the farnesoid X receptor, which regulates BA homeostasis (5, 6), and the pregnane X receptor and vitamin D receptor, which protect against the hepatotoxic actions of certain BAs (7, 8). TGR5 (GpBAR1 or M-BAR1) is a G protein-coupled receptor (GPCR) of the plasma membrane that interacts with multiple BAs that activate TGR5 with graded potencies (4, 9, 10). TGR5 is expressed in brown adipose tissue; skeletal muscle; immune, epithelial, and endothelial cells; and by enteric and primary spinal afferent neurons, where activation has biologically important consequences. In brown adipose tissue and skeletal muscle, TGR5 agonism results in the activation of thyroid hormone, leading to increased energy expenditure and weight loss (11). TGR5 activation on intestinal L cells stimulates release of glucagon-like peptide 1, an incretin that controls insulin secretion and glucose homeostasis and suppresses food intake and gastrointestinal transit (12, 13). In the gall bladder, TGR5 controls the composition and secretion of bile (14–17). Activation of TGR5 on macrophages and Kupffer cells inhibits cytokine release, phagocytosis, and lipid loading of macrophages (4, 9, 10) and diminishes hepatic and intestinal inflammation (4, 9, 18). In the intestine, luminal BAs can activate TGR5 on enterochromaffin cells and enteric neurons to release 5-hydroxytryptamine and calcitonin gene-related peptide, which induce peristalsis and mediate the well described prokinetic effects of bile (19, 20). BAs can also activate TGR5 expressed by primary spinal afferent and spinal neurons, and TGR5 mediates BA-evoked itch and analgesia, which may contribute to pruritus and painless jaundice that are observed in some patients with cholestatic disease (21). The identification of the biological actions of TGR5 has provided an impetus for the development of TGR5 agonists and antagonists as treatments for metabolic, inflammatory, digestive, and sensory disorders (4). However, the signal transduction mechanisms that give rise to the biological actions of TGR5 are not fully understood.

GPCR signals arise from multiprotein signaling complexes at the plasma membrane, in plasma membrane-associated compartments such as lipid rafts and caveolae, and in endosomes (22–24). The same receptor can transmit distinct signals from these different subcellular domains, with divergent physiological outcomes. Thus, an understanding of the mechanisms that regulate the subcellular location of GPCRs and the assembly and disassembly of these signaling complexes is key to understanding GPCR functions. For many GPCRs, G protein-coupled receptor kinases (GRKs) and β-arrestins play a central role in the spatiotemporal control of signaling (23). GRKs phosphorylate agonist-occupied receptors at the plasma membrane, which increases their affinity for β-arrestins, cytosolic proteins that translocate to the plasma membrane and interact with phosphorylated receptors. β-arrestins sterically uncouple GPCRs from heterotrimeric G proteins, which desensitizes plasma membrane signaling, and also couple receptors to clathrin and AP2, which mediate receptor endocytosis. By recruiting components of the MAPK cascade to internalized receptors, β-arrestins can also mediate sustained G protein-independent signaling from receptors in endosomes (23). TGR5 couples to Gαs, resulting in the activation of adenylate cyclase and formation of cAMP (9). TGR5 agonists also induce activation of MAPKs, including ERK1/2 and c-Jun-N-terminal kinase (25, 26), and TGR5 transactivates the epidermal growth factor receptor (EGFR), which, in turn, activates ERK1/2 (25, 27). However, it is unclear whether these signals derive from TGR5 that is localized to the plasma membrane, plasma membrane microdomains, or endosomes, and the mechanisms that control the duration of these signals are unknown.

In this study, we investigated TGR5 signaling in response to diverse endogenous and synthetic agonists. These included BAs (DCA, TLCA), a naturally occurring TGR5-selective agonist (oleanolic acid, OA) (28), and a highly potent synthetic agonist, 3-(2-chlorophenyl)-N-(4-chlorophenyl)-N, 5-dimethylisoxazole-4-carboxamide (CCDC) (29). We examined signaling and regulation of TGR5 expressed in a model cell line (HEK293 cells) and in non-transformed human colonocytes that naturally express this receptor (NCM460 cells). Our results show that TGR5 is a highly unusual GPCR that does not interact with β-arrestin1/2 or GRK2/5/6 when activated by its endogenous agonists. Consistent with these findings, BA-activated TGR5 does not traffic to endosomes. Activation results in the formation of cAMP at the plasma membrane and in the cytosol, but these signals do not undergo tachyphylaxis or desensitize to repeated stimulation. Instead, BA-activated TGR5 redistributes to plasma membrane microdomains, where association of TGR5 with the EGFR mediates efficient ERK1/2 signaling. This information about the spatiotemporal control of TGR5 signaling provides insight into the biological effects of BAs and is relevant to the mechanism of action of TGR5 agonists and antagonists that are under development for the treatment of diverse and debilitating diseases.

**EXPERIMENTAL PROCEDURES**

**Materials**—Primary antibodies were obtained from the following sources. Anti-HA11 (rabbit or rat) and anti-FLAG (mouse) were from Sigma-Aldrich (St. Louis, MO), anti-GFP (rabbit) was from Clontech (Mountainview, CA), anti-β-arrestin1/2 (rabbit) was from Abcam, Cambridge, MA), anti-EGFR (mouse) was from BD Biosciences), and anti-phospho-ERK1/2 (pERK, mouse) and anti-ERK2 (rabbit) were from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-rabbit or anti-mouse IgG conjugated to FITC or Rhodamine Red-X were from Jackson ImmunoResearch (West Grove, PA); goat anti-rabbit, anti-rat, and anti-mouse conjugated to Alexa Fluor 488, 594, or 647 were from Invitrogen; and goat anti-rabbit IgG conjugated to 10 nm of gold particles was from Ted Pella Inc. (Redding, CA). The protease-activated receptor 2 (PAR2) agonists SLIGRL-NH2 and 2-furoyl-LIGRLO-NH2 were from American
Peptide (Sunnyvale, CA), and the PAR₂ agonist AC 264613 was from Tocris (Ellisville, MO). The TGR5 agonist CCDC (29) was from BioVision (Milpitas, CA). Other reagents were from Sigma-Aldrich unless stated otherwise.

cDNAs—Human TGR5 with an N-terminal extracellular HA11 epitope (HA-TGR5) or C-terminal intracellular GFP (TGR5-GFP) and human PAR₂ with an N-terminal FLAG epitope (FLAG-PAR₂) have been described (20, 30). To generate luciferase-tagged receptors, cDNAs encoding human TGR5 or PAR₂ flanked by 5’ BamH1 and 3’ NotI restriction sites were generated by PCR using Phusion high-fidelity PCR (New England Biosciences, Ipswich, MA) with the following primers: TGR5 sense, cgc gga tcc atg ccc ccc aac aag act g and antisense, ata gtt tag cgg cag cag ggc gta gta cgg cgc taa act atc. PCR products were gel-purified and transferred into pDONR201 using BP Clonase II (Invitrogen). The construct was sub-cloned into pcDNA3-RLuc8 using the BamH1 and NotI sites. Human β-arrestin1 and β-arrestin2 with N-terminal GFP or YFP have been described (31). GRK2-Venus was amplified by PCR with the following primers to generate attB sites at either end of the DNA sequence: sense, ggg gac aag ctt cag caa aaa agc agg ctt cac cat ggc gga gct gga cct gga ggt g and antisense, ggg gac cac tgt ggc gag gtc gag gtc and antisense, tag ttt agg gca cgg agg gca taa tgt gaa aca ac a; PCR products were gel-purified and transferred into pcDNA3.1 (32). Kras-Venus, Rab5a-Venuse, and Rab7a-Venuse have been described (33). EGFR-Venus was provided by Dr. Kevin Pfleger (University of Western Australia). Gγ2-Venus, Gβ1, and Gα were generated as described (34). The cAMP BRET sensor CAMYEL (MBA-277) was from the ATCC. cAMP sensors on the basis of an exchange factor directly regulated by cAMP (Epac2) for measurement of global (glEpac2 and plasma membrane (pmEpac2)) cAMP levels were provided by Dr. Martin J. Lohse (University of Würzburg) and have been characterized previously (35). All constructs were sequenced to confirm identity.

Generation and Maintenance of Stably Transfected Cell Lines—Human embryonic kidney (HEK293) cells stably expressing HA-TGR5, TGR5-GFP, or FLAG-PAR₂ were generated using the FLP-In™ system (Invitrogen) and have been described (20, 36). HEK cell lines were cultured in DMEM supplemented with 10% heat-inactivated FBS and 100 μg/ml zeocin or hygromycin B. Human non-transformed colonic epithelial NCM460 colonocytes (Incell, San Antonio, TX) were cultured in M3D medium (Incell) containing 10% FBS. HA-TGR5 was stably expressed in NCM460 cells using a similar approach. Cell lines were cultured at 37 °C in 95% air, 5% CO₂.

TGR5, PAR₂, and β-Arrestin Trafficking—HEK-HA-TGR5 cells, HEK-TGR5-GFP cells, and NCM460-HA-TGR5 cells (3 × 10⁵/35-mm dish) were plated onto glass coverslips coated with poly-D-lysine (100 μg/ml) and were studied 24–48 h later. To assess trafficking of TGR5 and PAR₂ in the same cells, HEK-HA-TGR5 cells were transiently transfected with cDNA encoding FLAG-PAR₂ using Lipofectamine™ 2000 (Invitrogen) as described. To examine trafficking of receptors and β-arrestins, HEK-HA-TGR5 cells or HEK-FLAG-PAR₂ cells were transiently transfected with cDNAs encoding β-arrestin1 or β-arrestin2 with GFP or YFP tags. Cells were studied 24–48 h after transfection and plating. For trafficking assays, cells were incubated in DMEM containing 0.1% BSA at 37 °C and then challenged with TGR5 or PAR₂ agonists for 0–60 min. Receptors and β-arrestins were detected by immunofluorescence and confocal microscopy. To examine TGR5 trafficking in real time, HEK-TGR5-GFP cells grown on coverslips were incubated in Hanks’ balanced salt solution (HBSS) containing 20 mM HEPES at 37 °C. Cells were exposed to TGR5 agonists, and confocal images were collected at 5-min intervals for 60 min.

Immunofluorescence Labeling and Confocal Microscopy—Cells were washed in 100 mM PBS (pH 7.4) and fixed in 4% paraformaldehyde in PBS for 20 min at 4 °C. Cells were washed in PBS and incubated in blocking buffer (PBS containing 0.1% saponin and 1% normal goat serum) (3 × 10 min). Cells were incubated in blocking buffer with the following primary antibodies (all overnight at 4 °C): anti-HA11 (rabbit or rat, 1:200), anti-FLAG (mouse, 1:500), and anti-EGFR (mouse, 1:100). Cells were washed and incubated with fluorescent secondary antibodies (1:200, 2 h, room temperature). Cells were washed and mounted in Vectashield (Vector Laboratories, Burlingame, CA) or Prolong Gold (Invitrogen). Cells were observed with a Zeiss LSM Meta 510 laser-scanning confocal microscope (Carl Zeiss, Thornwood, NY) using a Fluor Plan Apochromat ×63 oil immersion objective (numerical aperture 1.4) or a Plan Apochromat ×100 oil immersion objective (numerical aperture 1.4) or were observed with a Leica TCS SP8 laser-scanning confocal microscope (North Ryde, New South Wales, Australia) using a Leica HCX PL APO ×63 oil immersion objective (numerical aperture 1.4).

Immunogold Labeling and Electron Microscopy—HEK293 cells were transiently transfected with TGR5-GFP or empty vector (vector control). Cells were stimulated with DCA (100 μM) or vehicle (control) for 30 min. In some experiments, cells were also incubated with methyl-β-cyclodextrin (20 μM) or vehicle (control). Cells were washed twice with PBS, fixed in 2% paraformaldehyde/0.1% glutaraldehyde/0.1 M cacodylate fixative (pH 7.4) (3 h, room temperature), dehydrated through ethanol, and embedded in L. R. White resin (Electron Microscopy Sciences, Hatfield, PA) according to the recommendations of the manufacturer. Ultrathin sections were prepared using a Leica Ultracut UCT microtome (Leica Microsystems Inc., IL). Sections were incubated with rabbit anti-GFP (1:200) or normal serum (overnight, room temperature). Sections were washed and incubated with goat anti-rabbit IgG conjugated to 10-nm particles (1:100, 45 min, room temperature). Sections were stained with 5% aqueous uranyl acetate as described and examined with a Philips Tecnai 10 electron microscope (FEI, Hillsboro, OR).
cAMP BRET CAMYEL assay—The BRET CAMYEL (cAMP sensor using YFP-Epac-RLuc) cAMP sensor permits quantification of intracellular cAMP levels with high sensitivity and a broad dynamic range (37). HEK293 and HEK-HA-TGR5 cells (4 × 10^5/10-cm plate) were transfected with 4 μg of cDNA encoding CAMYEL. Similarly, HEK293 cells were transfected with 1 μg of cDNA encoding TGR5-RLuc8 and 4 μg of CAMYEL. Cells were transfected using polyethyleneimine with a 6:1 polyethyleneimine:cDNA ratio in 500 μl of 0.15 M NaCl. Cells were incubated overnight in DMEM 10% FBS, washed in PBS, and incubated in 1 ml of versene for 10 min. Cells were plated onto poly-D-lysine-treated 96-well plates and maintained overnight. Cells were washed in HBSS and then incubated in HBSS for 30 min at 37 °C. Coelenterazine H (Promega, Madison, WI; 5 μM final) was added, and cells were incubated in the dark for 5 min at 37 °C. Luminescence for RLuc8 (480 nm) and YFP fluorescence (530 nm) was measured using a microplate reader (LUMInstar Omega, BMG Labtech, Mornington, Australia) for a 2-min basal period and for 10 min after addition of TGR5 agonists, forskolin (10 μM), or vehicle. Base-line and vehicle control values were subtracted, and the BRET signal was normalized as a percentage of the forskolin response.

FRET cAMP Assay—The FRET Epac-based cAMP sensors gEpac2 and pmEpac2 permit sensitive quantification of total cytoplasmic (global, gEpac2) and membrane-associated (plasma membrane, pmEpac2) cAMP levels and are suitable for studies of dynamic alterations in cAMP levels at the single cell level (38). HEK-HA-TGR5 cells were transfected with 4 μg cDNA encoding pmEpac2 or gEpac2 using polyethyleneimine and were plated onto 96-well plates. Cells were incubated in HBSS and observed using an IN Cell Analyzer 2000 (GE Healthcare BiSciences, Uppsala, Sweden) to measure the emission ratio of cyan fluorescent protein (470 nm) and yellow fluorescent protein (YFP; 535 nm). To assess the duration of cAMP signals, cells were incubated with the TGR5 agonist DCA (1 or 10 μM) or with isoprenaline (100 nM), an agonist of the endogenous β2 adrenergic receptors in HEK cells. To assess desensitization to a repeated challenge, cells were incubated with DCA (10 μM) or vehicle (control) for 10 min, washed six times in HBSS, and challenged with DCA (10 μM) 10 min after washing. At the end of the experiment, cells were challenged with 10 μM forskolin in the presence of 100 μM isobutylmethylxanthine. Images of individual cells were analyzed using ImageJ software (National Institutes of Health) as described (38, 39). The base line was subtracted from stimulated ratios, and results were normalized to the maximal response to the forskolin challenge. The criterion for exclusion of single cells was a maximal response smaller than 5% of the base-line ratio.

ERK1/2 Assays—For Western blot analysis of pERK, HEK-HA-TGR5 cells (5 × 10^5 cells/well) and NCM460 cells (2 × 10^5/well in a 12-well plate) were plated 48 h before treatments, and serum was replaced with 0.1% BSA for 16 h before assays. Cells were incubated in serum-free medium containing 0.1% BSA at 37 °C. Cells were challenged with DCA (100 μM), CCDC (10 μM), or EGF (10 ng/ml) for 0–60 min. At specified times, cells were lysed, and pERK was quantified according to the protocols of the manufacturer.

To determine the mechanism of ERK1/2 activation, cells were preincubated with vehicle (control), the EGFR tyrosine kinase inhibitor AG1478 (1 μM, Calbiochem), the metalloproteinase inhibitor batimastat (10 μM), and with methyl-β-cyclodextrin (500 μM) or filipin (1 μM), which deplete membrane cholesterol and block formation of lipid rafts. Inhibitors were preincubated with cells 30–60 min prior to stimulation with BAs and were present throughout the experiments.

BRET Assays to Assess Interactions of TGR5 and PAR2 with β-Arrestins, GRKs, Plasma Membrane and Endosomal Markers, G Proteins, and EGFR—To study the interactions of TGR5 and PAR2 with β-arrestins, GRKs, and plasma membrane and endosomal markers, HEK293 cells (4 × 10^5 cells/10-cm plate) were transiently transfected with 1 μg of cDNA encoding TGR5-RLuc8 or PAR2-RLuc8 plus 4 μg of β-arrestin1-YFP, β-arrestin2-YFP, GRK2-Venus, GRK5-Venus, GRK6-Venus, KRs-Venus, Rab5a-Venus, or Rab7a-Venus using polyethyleneimine (33, 40–42). Control cells were transfected with receptor-RLuc8 vector and pcDNA3.1 vector without insert. Cells were harvested 24 h post-transfection in HEPES-buffered phenol red-free complete medium containing 10% FBS (PR/FSB), plated onto poly-L-lysine-coated 96-well plates, and maintained at 37 °C, 5% CO2, for 24 h. Cells were incubated in fresh PR/FSB at 37 °C with coelenterazine h (5 μM final) and challenged with agonists of TGR5 or PAR2. Luminescence for RLuc8 (480 nm) and YFP or Venus fluorescence (530 nm) was measured using a microplate reader (LUMInstar Omega) at various times after stimulation. The net BRET ratio was determined by subtracting the BRET ratio of the RLuc8/pcDNA3.1 control from the experimental groups. The net BRET ratio was normalized to the base line and vehicle control.

To study interactions of TGR5 with G proteins, HEK293 cells (6 × 10^5 cells/well plate) were transiently transfected with 0.18 μg of cDNA encoding TGR5-RLuc8 plus 0.4 μg of Gly2-Venus, 0.27 μg of Gβ1, and 0.27 μg of Gα using GeneJuice (Novagen, Victoria, Australia). BRET was determined as described for other binding partners.

To study the interactions between TGR5 and EGFR by saturation analysis, HEK293 cells were transiently transfected with...
0.25 μg of cDNA encoding TGR5-RLuc8 plus graded amounts of EGFR-Venus (0.05, 0.075, 0.1, 0.125, 0.175, 0.5, 1, 1.25, 1.5, 1.625, and 1.75 μg) or empty vector using GenJuice. Cells were plated, and BRET was measured as described. The expression levels of TGR5-RLuc8 and EGFR-Venus were quantified by measurement of luminescence (LUMIstar Omega) and fluorescence (Envision, PerkinElmer Life Sciences), respectively. The BRET ratios were then compared with the protein expression ratios. In some experiments, cells were incubated with methyl-β-cyclodextrin (500 μM) or filipin (1.5 μM) for 60 min before the BRET assays.

**TGR5 RT-PCR**—Total RNA was isolated from HEK-TGR5-GFP and NCM460 cells and human colonic smooth muscle cells (ScienCell Research Laboratories, Carlsbad CA) using TRIzol™ (Invitrogen) and treated with DNase I (Ambion, Austin, TX). RNA (2 μg) was reverse-transcribed with Oligo d(T)15 and TaqMan reverse transcription reagents. PCR reactions used primers specific to human TGR5 (forward, 5'-tcgtctacttg-gctcacaac-3', +260 to +279; reverse, 5'-tcgctctgtggctagac-3', +757 to +776). To exclude contamination by genomic DNA, control reactions omitted reverse transcriptase. PCR products were separated by electrophoresis on a 2% gel, detected with ethidium bromide, and sequenced to confirm identity.

**β-Arrestin Western Blotting**—NCM460 cells were lysed, and lysates were separated by SDS-PAGE and blotted as described for ERK1/2 assays. Membranes were incubated with rabbit anti-arrestin 1/2 (1:1000, overnight, 4°C), washed, incubated with secondary antibodies, and then blots were analyzed with an Odyssey infrared imaging system (LiCOR Biosciences).

**Data and Statistical Analyses**—Quantitative analyses are from n = 3 independent experiments. Results were analyzed using PRISM 5 (GraphPad Software Inc., La Jolla, CA). Data are presented as mean ± S.E. Results were compared using two-way analysis of variance with Bonferroni post-test. A value of p < 0.05 was considered significant. Micrographs are representative of n = 3 independent experiments.

**RESULTS**

**TGR5 Expressed in HEK Cells Couples to Generation of cAMP**—To verify that TGR5 expressed in HEK cells is fully functional, we measured agonist-stimulated formation of cAMP by using the Epac-based BRET sensor CAMYEL, which permits the quantification of intracellular cAMP levels with high sensitivity and a broad dynamic range. In HEK cells stably expressing HA-TGR5 and transiently expressing CAMYEL, the endogenous TGR5 agonists DCA and TLCA (1 nM-100 μM, 5 min) stimulated a concentration-dependent increase in cAMP formation (Fig. 1A) (EC50, DCA, 70 nM; TLCA, 2.2 nM). OA, a naturally occurring component of leaves from the olive tree *Olea europaea* that potently activates TGR5 but not the nuclear farnesoid X BA receptor (43), also stimulated cAMP formation (EC50, 586 nM). The synthetic TGR5 agonist CCDC was the most potent stimulant of cAMP formation (EC50, 2.3 pM). DCA, TLCA, OA, and CCDC did not stimulate cAMP formation in HEK cells that did not express TGR5 (Fig. 1B). However, all
agonists stimulated cAMP formation in HEK cells expressing TGR5 with C-terminal tags that were used for BRET assays (RLuc8, Fig. 1C) and trafficking studies (GFP, Ref. 20). These results indicate that the agonists stimulate cAMP generation by a TGR5-dependent process and that tagged versions of TGR5 are fully functional.

**TGR5 Is Localized to the Plasma Membrane and Does Not Undergo Agonist-induced Endocytosis**—Upon activation, many GPCRs traffic from the plasma membrane to endosomes by a clathrin- and dynamin-dependent mechanism (22, 23). To determine whether BAs that activate TGR5 also stimulate receptor endocytosis, we used sequential confocal imaging to study the trafficking in real time of TGR5-GFP expressed in HEK cells. In unstimulated cells, TGR5-GFP was present at the plasma membrane with minimal intracellular pools (Fig. 2A). Exposure to DCA (100 μM, 37 °C) did not alter the subcellular distribution of TGR5, which remained at the plasma membrane for up to 60 min of stimulation. We also examined the subcellular localization of HA-TGR5 expressed in HEK cells. Cells were incubated with vehicle (0.1% ethanol) or DCA, TLCA, OA, or CCDC (100 μM) for 10 min, showing the retention of TGR5 at the plasma membrane (arrowheads). C and D, trafficking of TGR5 and PAR2. TGR5-GFP and FLAG-PAR2 were coexpressed in HEK cells. Cells were incubated with DCA (100 μM) or PAR2-AP (SLIGRL-NH2,50 μM, D) for 30 min, and both receptors were localized simultaneously. DCA did not affect the subcellular localization of TGR5 or PAR2, which remained at the plasma membrane (arrowheads). In contrast, PAR2-AP stimulated the trafficking of PAR2 to endosomes (arrows). Scale bars = 10 μm. Shown are representative images of n ≥ 3 experiments.
Activated TGR5 Does Not Traffic through the Endosomal Network—To further investigate the subcellular location of TGR5 upon agonist stimulation, we used a recently described BRET assay that allows the detection of energy transfer between receptors and BRET partners targeted to defined subcellular compartments (33). This approach allows quantitative assessment of receptor trafficking from the plasma membrane to defined populations of endosomes. To do so, TGR5-RLuc8 or PAR2-RLuc8 were coexpressed in HEK293 cells with Venus-tagged BRET acceptors that are localized to different compartments: KRas-Venus at the plasma membrane, Rab5a-Venus in early endosomes, and Rab7a-Venus in late endosomes/lysosomes. Cells were incubated with agonists of TGR5 or PAR2 for 30 min at 37 °C. Coelenterazine h was added in the last 10 min of the agonist incubation, and then BRET was measured. The potent PAR2 agonists 2-Fluoryl-LIGRLO-NH2 and AC 264613 (both 10 μM) resulted in a significant decrease of the BRET signal between PAR2-RLuc8 and Venus-KRas, indicative of receptor endocytosis (Fig. 3A). The decline in BRET signals between PAR2 and the plasma membrane acceptor coincided with a significant increase in the BRET signals between PAR2-RLuc8 and Rab5a-Venus and Rab7a-Venus (Fig. 3, B and C). These results are consistent with the expected accumulation of PAR2 in Rab5a-positive early endosomes and Rab7a-positive late endosomes/lysosomes. In contrast, when cells were incubated with the TGR5 agonists DCA, TLCA, CCDC (all 100 μM), or OA (10 μM), there was no significant change in BRET between TGR5-RLuc8 and KRas-Venus, suggesting lack of internalization (Fig. 3A). Incubation with TLCA and CCDC caused a small increase in BRET between TGR5-RLuc8 and Rab5a-Venus or Rab7a-Venus, although this was significant only for Rab7a-Venus and CCDC (Fig. 3, B and C). Considered together, these results are consistent with the microscopy and indicate that TGR5 does not undergo robust agonist-stimulated endocytosis.

Activated TGR5 Does Not Recruit β-Arrestin1 or β-Arrestin2—Agonists of many GPCRs promote the recruitment of β-арrestins to GRK-phosphorylated receptors at the plasma membrane, where β-арrestins uncouple receptors from heterotrimeric G proteins and desensitize plasma membrane signaling (22, 23, 44). β-аррестинs also couple receptors to clathrin and AP2, which mediate endocytosis of the receptor and β-арrestin complex. To determine whether TGR5 activation similarly induces the recruitment of β-аррестинs to the plasma membrane or endosomes, we transiently expressed β-аррестин1 or β-аррестин2 with GFP or YFP tags in HEK-HA-TGR5 cells. Cells were incubated with TGR5 agonists, and HA-TGR5 and β-аррестин1-GFP or β-аррестин2-GFP were localized by immunofluorescence and confocal microscopy. In unstimulated cells, TGR5 was at the plasma membrane, and β-аррестин1-GFP and β-аррестин2-GFP were distributed uniformly in the cytosol (Fig. 4, A and B). Incubation with DCA (100 μM) for 5 or 30 min did not alter this significant effect on the TGR5-RLuc8 and Rab5a-Venus and Rab7a-Venus BRET, with the exception of CCDC, which increased TGR5-RLuc8 and Rab7a-Venus BRET. Thus, TGR5 agonists do not cause a robust trafficking of TGR5 from the plasma membrane to early and late endosomes. *, p < 0.05 to vehicle. Shown are triplicate observations from n = 3 experiments.

FIGURE 3. BRET analysis of interactions between PAR2 or TGR5 with plasma membrane and endosomal markers. PAR2-RLuc8 or TGR5R-RLuc8 was coexpressed with the plasma membrane BRET acceptor KRas-Venus (A), the early endosomal BRET acceptor Rab5a-Venus (B), or the late endosomal BRET acceptor Rab7a-Venus (C) in HEK293 cells. Cells were incubated with vehicle or with agonists of PAR2 (orange) or TGR5 (blue) for 30 min, and BRET signals were measured. The PAR2 agonists 2-fluoryl-LIGRLO (2-fluoryl) and AC264613 (AC26) (both 10 μM) induced a decline in PAR2-RLuc8 and KRas-Venus BRET and an increase in PAR2-RLuc8 and Rab5a-Venus and Rab7a-Venus BRET, indicative of trafficking of PAR2 from the plasma membrane to early and late endosomes. The TGR5 agonists DCA, TLCA, CCDC (100 μM), or OA (10 μM) did not affect TGR5-RLuc8 and KRas-Venus BRET and had no sig-
subcellular distribution of TGR5 or cause trafficking of β-arrestin1-GFP or β-arrestin2-GFP from the cytosol to the plasma membrane or endosomes. Similarly, exposure of cells to TLCA, OA, or CCDC (100 μM) for 5 or 30 min did not affect the subcellular distribution of TGR5, β-arrestin1-YFP (not shown), or β-arrestin2-YFP (Fig. 4C, 30 min). In marked contrast, PAR2-AP (SLIGRL-NH2, 50 μM, 30 min) stimulated trafficking of FLAG-PAR2 and β-arrestin2-GFP (not shown) to the same endosomes. These results suggest that agonists do not promote the interaction of TGR5 with β-arrestin1 or β-arrestin2 in HEK cells.

Activated TGR5 Does Not Internalize or Interact with β-Arrestins in Human Colonocytes That Naturally Express This Receptor—To ascertain whether agonists promote TGR5 and β-arrestin trafficking in cells that naturally express these proteins, we studied NCM460 cells, a non-transformed human colonic epithelial cell line that has been used to assess the interactions between GPCRs and accessory proteins, such as β-arrestins (31). To quantitatively assess the interactions between TGR5 and β-arrestin1 or β-arrestin2, HEK cells were cotransfected with RLuc8-tagged TGR5 and YFP-tagged β-arrestins. As a positive control, RLuc8-tagged PAR2 and YFP-tagged β-arrestins were coexpressed similarly. Cells were incubated with coelenterazine h for 5 min, and BRET signals were measured before and after agonist stimulation. The PAR2 agonists 2-furoyl-LIGRLO-NH2 and AC 264613 (both 10 μM) stimulated an immediate and robust BRET signal between PAR2 and β-arrestin1-YFP or

FIGURE 4. Agonist-stimulated trafficking of TGR5, PAR2, and β-arrestins (βARR). A–C, HEK-HA-TGR5 cells were transiently transfected with β-arrestin1-GFP (A), β-arrestin2-GFP (B), or β-arrestin2-YFP (C). Cells were incubated with DCA, TLCA, OA, or CCDC (all 100 μM) for 0–30 min, and TGR5 and β-arrestins were localized. The merged images in C show HA-TGR5 (red) and β-arrestin2-YFP (green). DCA, TLCA, OA, and CCDC did not alter the subcellular distribution of TGR5, which remained at the plasma membrane (arrowheads), or β-arrestins, which remained in the cytosol (arrows) at every time point. D, HEK-FLAG-PAR2 cells were transiently transfected with β-arrestin1-GFP. Cells were incubated with PAR2-AP (SLIGRL-NH2, 50 μM) for 30 min, which induced trafficking of PAR2 and β-arrestin1-GFP to the same endosomes (arrows). Scale bars = 10 μm. Shown are representative images of n ≥ 3 experiments.
β-arrestin2-YFP, consistent with interactions between PAR2 and β-arrestins (Fig. 6, A and B). Stimulation with graded concentrations of these agonists (1 nM-1 mM, 5 min) revealed a concentration-dependent BRET signal (Fig. 6, C and D). In marked contrast, stimulation of cells with the TGR5 agonists DCA, OA, or TLCA (1 nM-1 mM) did not result in an increase in the BRET signal between TGR5-RLuc8 and β-arrestin1-YFP or β-arrestin2-YFP over the base line (Fig. 6, A and B).

GRK2, GRK5 and GRK6 can interact with and phosphorylate many agonist-occupied GPCRs, which promotes the recruitment of β-arrestins. To assess whether agonists of PAR2 and TGR5 induce the interaction between receptors and GRKs, we cotransfected HEK cells with RLuc8-tagged receptors and GRK2-Venus, GRK5-Venus or GRK6-Venus. The PAR2 agonists 2-furoyl-LIGRLO-NH2 and AC 264613 (both 10 μM) stimulated an immediate and robust BRET signal between PAR2-RLuc8 and GRK2-Venus (Fig. 6E), and 2-furoyl-LIGRLO-NH2 also induced BRET between PAR2-RLuc8 and GRK5-Venus (F) and GRK6-Venus (G). In contrast, DCA, OA, or TLCA (all 100 μM) did not increase the BRET signal between TGR5-RLuc8 and GRK2-Venus (Fig. 6E), and DCA did not cause an increased BRET signal between TGR5-RLuc8 and GRK5-Venus (F) and GRK6-Venus (G). The DCA-evoked decline in BRET between TGR5-RLuc8 and GRK5-Venus may reflect a conformational change in TGR5 at the plasma membrane.

Thus, although PAR2 agonists promote the interaction between PAR2 and GRK2/5/6 and β-arrestin1/2, TGR5 agonists do not stimulate interactions between TGR5 and GRK2/5/6 and β-arrestin1/2. These results are consistent with the inability of TGR5 agonists to stimulate detectable endocytosis of the receptor or redistribution of the subcellular distribution of β-arrestins.

Activation of TGR5 with a Synthetic Agonist Results in β-Arrestin2 and GRK2 Recruitment—CCDC is a synthetic agonist of TGR5 (29) that is a more potent stimulant of cAMP formation than endogenous BA agonists (Fig. 1). We used BRET to determine whether CCDC could promote the interaction of TGR5 with β-arrestin1/2 or GRK2/5/6. Strikingly, CCDC (100 μM) stimulated the preferential interaction between TGR5-RLuc8 and β-arrestin2-YFP but not β-arrestin1-YFP (Fig. 7, A and B). CCDC also stimulated the interaction between TGR5-RLuc8 and β-arrestin2-YFP.
and GRK2-Venus (Fig. 7C) but not between TGR5-RLuc8 and GRK5-Venus or GRK6-Venus (D). However, although CCDC induced a significant increase in the BRET signal between TGR5-RLuc8 and β-arrestin1-YFP and β-arrestin2-YFP (p < 0.0001 for all time points after 2 min). The interaction of PAR2-RLuc8 and β-arrestin1-YFP (C) and β-arrestin2-YFP (D) was concentration-dependent (measured at 5 min). In contrast, DCA, TLCA, and OA failed to induce an increase in BRET between TGR5-RLuc8 and β-arrestin1-YFP (A and C, p > 0.05) or β-arrestin2-YFP (B and D, p > 0.05). E–G, PAR2-RLuc8 or TGR5RLuc8 was coexpressed with GRK2-Venus, GRK5-Venus, or GRK6-Venus in HEK cells. When compared with prestimulated values, the PAR2 agonists AC264613 and 2-furoyl-LIGRLO (both 10 μM, arrows) induced a rapid and sustained increase in the BRET signal from PAR2-RLuc8 to GRK2-Venus (E), GRK5-Venus (F), and GRK6-Venus (G) (p < 0.0001 for all time points after 2 min). In contrast, DCA, TLCA, and OA did not evoke an increase in the BRET signal between TGR5-RLuc8 and GRK2-Venus, GRK5-Venus, or GRK6-Venus (p > 0.05 for all time points after 2 min). Shown are triplicate observations from n = 3 experiments.

and GRK2-Venus (Fig. 7C) but not between TGR5-RLuc8 and GRK5-Venus or GRK6-Venues (D). However, although CCDC induced a significant increase in the BRET signal between TGR5-RLuc8 and β-arrestin1-YFP and β-arrestin2-YFP and GRK2-Venus, the BRET signals were ~2-fold lower than those for PAR2-RLuc8 and β-arrestin2-YFP and 3-fold lower than those for PAR2-RLuc8 and GRK2-Venus. Moreover, CCDC did not induce a detectable redistribution of β-arrestin2-GFP to the plasma membrane or endosomes and did not stimulate endocytosis of TGR5 (Figs. 3A and 4C). Thus, the highly potent agonist CCDC can induce the preferential interaction between TGR5 and β-arrestin2 and GRK2 but
not β-arrestin1 or GRK5/6. These interactions are insufficient to support endocytosis of TGR5.

**TGR5 Couples to Gαs and Induces Sustained cAMP Signals That Do Not Desensitize Robustly**—To investigate the interaction between TGR5 and Gα proteins, we examined BRET between TGR5-RLuc8 and GRα2-Venus (34). In HEK293 cells expressing TGR5-RLuc8, GRα2-Venus, GRK5-Venus, or GRK6-Venus in HEK cells, A, when compared with pre-stimulated values, the synthetic TGR5 agonist CCDC (100 μM, arrow) did not affect the BRET signal between TGR5-RLuc8 and β-arrestin1-YFP (p > 0.05 for all time points after 2 min) but induced a rapid and sustained increase in the BRET signal between TGR5-RLuc8 and β-arrestin2-YFP (p < 0.0001 for all time points after 2 min). B, CCDC stimulated a BRET signal between TGR5-RLuc8 and β-arrestin2-YFP only at the highest concentrations (measured after 5 min) C, CCDC (100 μM, arrow) also stimulated a BRET signal between TGR5-RLuc8 and GRK2-Venus (p < 0.0001 for all time points after 2 min). D, CCDC (100 μM, arrow) did not stimulate a BRET signal between TGR5-RLuc8 and GRK5/6-Venus (p > 0.05 for all time points after 2 min). Shown are triplicate observations from n = 3 experiments.

FIGURE 7. CCDC-induced interaction of TGR5 with β-arrestins and GRKs. TGR5-RLuc8 was coexpressed with β-arrestin1-YFP, β-arrestin2-YFP, GRK2-Venus, GRK5-Venus, or GRK6-Venus in HEK cells. A, when compared with pre-stimulated values, the synthetic TGR5 agonist CCDC (100 μM, arrow) did not affect the BRET signal between TGR5-RLuc8 and β-arrestin1-YFP (p > 0.05 for all time points after 2 min) but induced a rapid and sustained increase in the BRET signal between TGR5-RLuc8 and β-arrestin2-YFP (p < 0.0001 for all time points after 2 min). B, CCDC stimulated a BRET signal between TGR5-RLuc8 and β-arrestin2-YFP only at the highest concentrations (measured after 5 min). C, CCDC (100 μM, arrow) also stimulated a BRET signal between TGR5-RLuc8 and GRK2-Venus (p < 0.0001 for all time points after 2 min). D, CCDC (100 μM, arrow) did not stimulate a BRET signal between TGR5-RLuc8 and GRK5/6-Venus (p > 0.05 for all time points after 2 min). Shown are triplicate observations from n = 3 experiments.

These results indicate that CCDC-evoked cAMP formation in the cytoplasm and at the plasma membrane does not undergo tachyphylaxis and is not attenuated in response to a repeated challenge. Thus, in contrast to the β2 adrenergic receptor, which undergoes well documented desensitization, TGR5 is remarkably resistant to desensitization and is capable of continuing to signal from the plasma membrane for prolonged periods. This lack of desensitization is consistent with the inability of TGR5 to interact with GRK2/5/6 and β-arrestin1/2, which desensitize plasma membrane signaling of many other GPCRs, including PAR1, and the β2 adrenergic receptor.

**TGR5 Transactivates the EGFR within Plasma Membrane Microdomains to Stimulate ERK1/2**—GPCRs can activate ERK1/2 by G protein-dependent and independent mechanisms. A prominent G protein-dependent mechanism that operates from the plasma membrane involves G protein-mediated activation of membrane metalloproteases that cleave and liberate membrane-tethered agonists of the EGFR, leading to EGFR-mediated ERK1/2 activation (i.e. EGFR transactivation) (47). By recruiting components of the MAP kinase cascade such as src and raf-1 to internalized GPCRs, β-arrestins can mediate G protein-independent ERK1/2 activation (23, 48). To determine whether TGR5 activates ERK1/2 by these mechanisms, we challenged HEK-HA-TGR5 cells with DCA (100 μM) and assessed ERK1/2 activation by Western blotting for pERK1/2 and ERK2. DCA stimulated a robust increase in levels of pERK1/2 that was maximal after 2 min and sustained for at least 30 min (Fig. 9, A and C). The EGFR tyrosine kinase inhibitor AG1478 strongly inhibited DCA-stimulated ERK1/2 activation (Fig. 9, B and C).

The compartmentalization of GPCRs within microdomains at the plasma membrane, including lipid rafts and caveolae, can enhance the efficiency of signal transduction (24). Cholesterol is enriched in lipid rafts and caveolae, and agents that deplete the plasma membrane of cholesterol, including methyl-β-cyclohextrin and filipin, disrupt assembly of lipid rafts and caveolae.
To determine whether compartmentalization is necessary for TGR5-mediated transactivation of the EGFR and activation of ERK1/2, we treated cells with methyl-H9252-cyclodextrin or filipin and examined DCA-stimulated ERK1/2 activation by Western blotting. Both treatments strongly inhibited DCA-stimulated activation of ERK1/2 (Fig. 9, D–G).

To examine the mechanisms by which endogenously expressed TGR5 activates ERK1/2, we measured ERK1/2 activation in NCM460 cells using the highly sensitive AlphaScreen phospho-ERK assay. We first verified that this assay gave similar results in HEK-TGR5 cells as the Western blot assay for ERK1/2 activation. As expected, DCA (100 μM) and CCDC (10 μM) both stimulated ERK1/2 activation (Fig. 10A). The EGFR tyrosine kinase inhibitor AG1478 and the metalloprotease inhibitor batimastat both abolished DCA- and CCDC-evoked ERK activation. Similarly, in non-transfected NCM460 colonocytes, DCA (100 μM, 5 min) ERK activation was inhibited by 78% by filipin (p > 0.0001) and 50% by methyl-β-cyclodextrin (p > 0.01) (not shown). In marked contrast, filipin or methyl-β-cyclodextrin did not inhibit EGF-stimulated ERK activation in NCM460 cells, and these agents did not inhibit DCA-evoked cAMP formation in HEK-TGR5 cells (not shown).

These results indicate that TGR5 transactivates the EGFR to induce the activation of ERK1/2. This transactivation requires activity of a batimastat-sensitive proteases and occurs within...
plasma membrane microdomains, which probably serve to increase the efficiency of TGR5-stimulated EGFR transactivation and ERK1/2 signaling. However, TGR5-dependent cAMP formation does not require intact lipid rafts because it was not inhibited by filipin or methyl-β-cyclodextrin.

**TGR5 and EGFR Form Heterodimers within Plasma Membrane Microdomains**—The association between GPCRs and the EGFR within plasma membrane microdomains can enhance the efficiency of EGFR transactivation and ERK1/2 signaling (49–51). In HEK-HA-TGR5 cells, TGR5 and endogenous EGFR were colocalized at the plasma membrane (Fig. 11A). To determine whether TGR5 associates with EGFR, we examined interactions between TGR5-RLuc8 and EGFR-Venus using BRET. Saturation curves were generated by expressing a constant amount of TGR5-RLuc8 with increasing amounts of EGFR-Venus expression, with a maximal BRET ratio of ~0.03 (Fig. 11B). These data are consistent with the preassembly of TGR5 and EGFR heterodimers, even in the absence of the agonist. In cells treated with filipin, which depletes membrane cholesterol and blocks formation of lipid rafts, the TGR5 and EGFR interactions did not saturate (Fig. 11B). Methyl-β-cyclodextrin also blocked saturation, although to a lesser degree than filipin (not shown).

Kinetic BRET assays were used to assess the effects of TGR5 agonists on TGR5 and EGFR interactions. DCA (100 μM), OA (10 μM), or CCDC (10 μM) had no effect on the BRET signal between TGR5-RLuc8 and EGFR-Venus (Fig. 11C). These results suggest that TGR5 and EGFR form a heterodimer that efficiently assembles in plasma membrane lipid rafts. The formation of this dimer is unaffected by TGR5 agonists.

**Activated TGR5 Redistributes to Plasma Membrane Rafts**—Confocal microscopy lacks the resolution to precisely localize receptors to plasma membrane microdomains. Therefore, we
used immunogold labeling and electron microscopy to determine whether TGR5 agonists stimulated the redistribution of TGR5 to plasma membrane rafts. HEK-TGR5-GFP cells were incubated with DCA (100 μM) or CCDC (10 μM) (0–60 min, 37 °C). pERK was measured using the AlphaScreen assay. DCA and CCDC stimulated ERK activation in both cell lines. When compared with agonist alone, AG1478 or batimastat abolished activation of ERK (all p < 0.0001 at 5 and 10 min). Shown are triplicate observations from n = 3 experiments.

DISCUSSION

We have investigated the spatiotemporal control of signaling of TGR5, a plasma membrane receptor for BAs. Our results reveal several unusual aspects of TGR5 signaling, trafficking, and regulation. First, diverse natural (DCA, TLCA, and OA) and synthetic (CCDA) agonists that robustly activate TGR5 did not induce TGR5 trafficking from the plasma membrane to endosomes. Second, except for very high concentrations of CCDC, a potent TGR5 agonist, these agonists did not induce alterations in the subcellular distribution of β-arrestins or promote detectable interactions of β-arrestin1/2 and GRK2/5/6 with TGR5. Third, TGR5 agonists stimulated interaction between TGR5 and Gαs and the formation of cAMP at the plasma membrane and in the cytosol. However, cAMP generation did not exhibit tachyphylaxis or a diminished response to repeated stimulation, which are both indicative of a lack of desensitization. Fourth, TGR5 associates with and transactivates the EGFR within lipid rafts at the plasma membrane, which leads to activation of ERK1/2. These findings provide insight into the biological actions of BAs that are mediated by TGR5 and are of relevance to the properties of TGR5 agonists/antagonists that are under development for the treatment of metabolic, inflammatory, digestive, and sensory disorders.

Agonist-induced Trafficking of TGR5—Many activated receptors, including the β, adrenergic receptors, PAR2, neurokinin 1 receptor, and μ- and δ-opioid receptors, traffic from the plasma membrane to endosomes (22, 23). Endosomal sorting then targets the internalized receptors back to the plasma membrane, where recycling mediates resensitization (e.g. β2 adrenergic receptor, neurokinin 1 receptor, μ-opioid receptor), or to lysosomes, where degradation mediates receptor down-regulation (e.g. PAR2, δ-opioid receptor). Our results show that TGR5 is prominently localized to the plasma membrane when expressed in HEK293 cells and in NCM460 colonocytes, which express endogenous TGR5. Surprisingly, stimulation of these cells with diverse agonists of TGR5, including endogenous agonists (DCA, TLCA), a naturally occurring selective agonist (OA), and a highly potent synthetic agonist (CCDA), did not induce detectable trafficking of TGR5 to endosomes, as determined by immunofluorescence and confocal microscopy and by using BRET. All of these agents activated TGR5, as assessed by measurement of cAMP formation. In marked contrast, agonists of PAR2, which was coexpressed in HEK cells with TGR5, induced robust endocytosis of PAR2. These results confirm our earlier reports of agonist-stimulated endocytosis of PAR2 (30) and indicate that the HEK cell line was fully capable of supporting GPCR endocytosis. Moreover, other GPCRs, including the neurotensin 1 receptor (45) and neurokinin 1 receptor4, undergo agonist-stimulated endocytosis in NCM460 colonocytes.

β-arrestins are key regulators of GPCR signaling and trafficking. β-arrestins interact with agonist-occupied and GRK-phosphorylated receptors with graded affinities, depending upon the extent of receptor phosphorylation. “Class A” GPCRs (e.g. β2 adrenergic receptor, bradykinin B2 receptor, μ-opioid receptor, neurokinin 3 receptor) have few GRK phosphorylation sites, exhibit selective, low affinity and transient interactions with β-arrestin2, and recycle rapidly (52–54). “Class B” GPCRs (e.g. neurokinin 1 receptor, neurotensin 1 receptor, vasopressin V2 receptor) are highly phosphorylated, interact with both β-arrestin1 and 2 with high affinity for prolonged periods in endosomes, and recycle slowly. TGR5 is unusual,

4 N. W. Bunnett, unpublished data.
belonging to neither category of receptor. None of the tested agonists induced detectable redistribution of β-arrestin1 or β-arrestin2 expressed in HEK293 or NCM460 cells, as assessed by confocal microscopy. Analysis of TGR5 and β-arrestin interactions by BRET, a sensitive and quantitative assessment of GPCR and β-arrestin interactions, generally confirmed these results. Thus, DCA, TLCA, and OA did not induce BRET signals between TGR5 and β-arrestin1/2 or GRK2/5/6, whereas in the same cells, agonists of PAR2 stimulated strong BRET interactions between PAR2 and these proteins, in line with other reports (55). CCDC alone caused a small BRET signal between TGR5, β-arrestin2, and GRK2, but this was only apparent at high CCDC concentrations, and there was no signal between TGR5 and β-arrestin1 or GRK5/6. Our results contradict an earlier report that TGR5-GFP traffics to endosomes in CHO cells (9). The reason for this difference could be related to differences in cell types, although, in this study, we confirmed the lack of TGR5 endo-

FIGURE 11. TGR5 and EGFR interactions in HEK293 cells. A, localization of HA-TGR5 and EGFR in HEK-HA-TGR5 cells. TGR5 was at the plasma membrane (arrowheads), and EGFR was detected in vesicles located beneath the plasma membrane and also at the plasma membrane (arrowheads). Scale bar = 10 μm. B and C, BRET analysis between TGR5-RLuc8 and EGFR-Venus expressed in HEK293 cells. B, saturation analysis of ligand-independent interactions. A fixed amount of TGR5-RLuc8 and graded amounts of EGFR-Venus were coexpressed in HEK293 cells. The BRET ratios are plotted as a function of the protein expression ratio of [EGFR-Venus]/[TGR5-RLuc8]. The saturation curves were fitted using a non-linear regression equation assuming a single binding site (GraphPad Prism). Note that TGR5-RLuc8 and EGFR-Venus interactions saturate, and that filipin prevents saturation. C, real-time BRET ratios between TGR5-RLuc8 and EGFR-Venus before and after stimulation with DCA (100 μM), OA (10 μM), or CCDC (10 μM) (arrow). TGR5 agonists did not affect the TGR5-RLuc8 and EGFR-Venus BRET ratio. Shown are triplicate observations from n = 3 experiments.
cytosis in a cell line that naturally expresses this receptor (NCM460 colonocytes).

β-arrestins couple GPCRs to clathrin and AP2 and, thereby, mediate endocytosis of many receptors, including PAR2 (23, 44). Our observation that agonists do not recruit GRK2/5/6 or β-arrestin1/2 to TGR5 is thus consistent with the lack of agonist-stimulated endocytosis of TGR5. The structural basis for the inability of TGR5 to recruit β-arrestins and traffic to endosomes is unknown. One possibility is that TGR5 is resistant to GRK-mediated phosphorylation. However, although TGR5 did not interact robustly with GRK2/5/6, TGR5 does contain a series of serines within the intracellular carboxyl-terminal domain that are predicted sites for phosphorylation by GRKs (56). Further studies are required to assess whether TGR5 agonists cause phosphorylation of this receptor.

Although uncommon, agonists of some other GPCRs also fail to induce β-arrestin recruitment and receptor endocytosis. For example, enkephalins, endorphin, and etorphine recruit β-arrestins to the μ-opioid receptor and stimulate robust receptor endocytosis, but morphine is generally less effective, and heroin does not cause β-arrestin2 recruitment or receptor endocytosis (57–61).

Although TGR5 did not traffic to endosomes, DCA did induce the redistribution of TGR5 to plasma membrane domains, which were detected by immunogold labeling of TGR5 and electron microscopy. The identity of these compartments is not known, although they likely correspond to lipid rafts because treatment of cells with methyl-β-cyclodextrin, which depletes the plasma membrane of cholesterol and blocks formation of lipid rafts, prevented TGR5 trafficking to these domains. Further studies are required to define the nature and composition of these domains. Other GPCRs are also present in lipid rafts, both basally and after agonist stimulation, including neurokinin, opioid, and bradykinin receptors (24). Although further studies are required to define the nature of these TGR5-containing lipid domains, the concentration of GPCRs and related signaling proteins within such microdomains can enhance the efficiency and fidelity of signal transduction (24).

**FIGURE 12. Agonist-induced redistribution of TGR5 to plasma membrane rafts.** HEK-TGR5-GFP cells were incubated with vehicle (A and C) or DCA (100 μM, 30 min, B and D). TGR5 was localized by immunogold labeling and electron microscopy using an antibody to GFP. In some experiments, cells were treated with vehicle or methyl-β-cyclodextrin (MβCD). A, in vehicle-treated cells, TGR5 was present predominantly at the cell surface (arrowheads). B, DCA evoked the redistribution of TGR5 to vacuoles located close to the cell surface. C, in vehicle- and methyl-β-cyclodextrin-treated cells, TGR5 was at the cell surface (arrowheads). D, methyl-β-cyclodextrin prevented DCA-induced redistribution of TGR5 to vacuoles and caused retention of TGR5 at the cell surface (arrowheads). Scale bar = 1 μm. Shown are representative images from n > 3 experiments.

The Spatiotemporal Control of TGR5 Signaling—GPCR signaling must be under tight physiological control because dysregulated signaling can cause disease. Regulation at the level of the receptor can include processes that control the duration of receptor interaction with heterotrimeric G proteins or that regulate the subcellular location of the receptor and, thus, its proximity to signaling proteins. By using FRET sensors on the basis of Epac2 that allow quantitative assessment of the subcellular location and time course of cAMP formation (38), we observed that DCA evoked the generation of cAMP at the plasma membrane and in the cytosol. Remarkably, cAMP formation was completely sustained in the continued presence of DCA for at least 100 min. There was no evidence of tachyphylaxis of this signal, although cAMP levels quickly declined when the cells were washed. In contrast, isoprenaline-stimulated formation of cAMP underwent tachyphylaxis. This lack of desensitization of DCA-evoked formation of cAMP is consistent with the inability of DCA to induce the recruitment of β-arrestins to TGR5 because β-arrestins play a central role in receptor desensitization. Although compartmentalized signaling is a key determinant of the specific actions of GPCRs, further studies are required to define the functional importance of TGR5-mediated...
TGR5 Signaling

ated generation of cAMP at the plasma membrane and throughout the cell. The generation of cAMP at the plasma membrane may allow TGR5 to efficiently activate ion channels. Thus, BAs activate TGR5 on primary spinal afferent neurons to induce enhanced excitability and scratching behavior (21) by a mechanism that involves activation of transient receptor potential ankyrin 1 at the plasma membrane by a cAMP and protein kinase A-dependent process.

In addition to stimulating the formation of cAMP at the plasma membrane, TGR5 at the plasma membrane also stimulated activation of ERK1/2 by a mechanism that involved activation of a membrane metalloprotease and transactivation of the EGFR because DCA-stimulated ERK1/2 activation was prevented by a metalloprotease inhibitor (batimatastat) and an inhibitor of the EGFR tyrosine kinase (AG1478). These findings support other reports that TGR5 transactivates the EGFR (25, 27). We observed that methyl-β-cyclodextrin and filipin, which disrupt lipid rafts and caveolae by depleting cholesterol, also blocked DCA-stimulated ERK1/2 activation. Our results suggest that TGR5-mediated transactivation of the EGFR occurs within lipid rafts. By using BRET to assess interactions between TGR5-RLuc8 and EGFR-Venus, we observed the existence of preassembled heterodimers between TGR5 and EGFR. Filipin and methyl-β-cyclodextrin prevented the assembly of these heterodimers, suggesting that they assemble efficiently in lipid rafts. Although we do not know whether TGR5 interacts directly with EGFR or whether they are part of a multiprotein complex, other GPCRs can interact with the EGFR in lipid rafts, which can enhance the efficiency of signaling. For example, agonists promote the formation of a multiprotein complex containing the angiotensin 1 receptor and EGFR that is necessary for efficient signaling in hepatic C9 cells (50, 51). Similarly, isoprenaline stimulates the assembly of complexes containing the β3 adrenergic receptor and EGFR in COS-7 cells (49).

Considered together, our results suggest that TGR5 and EGFR form heterodimers within lipid rafts that promote the efficient BA-induced transactivation of the EGFR by a mechanism that involves activation of a membrane metalloprotease, release of an unidentified EGFR agonist, and autocrine activation of EGFR. This mechanism operates in HEK cells and in NCM460 colonocytes that express endogenous TGR5 and ensures efficient ERK activation. Although lipid rafts are essential for TGR5 interaction with EGFR, transactivation of the EGFR, and ERK signaling, they are not required for direct EGFR activation of EGFR and ERK signaling or for TGR5-mediated cAMP generation, which were unaffected by filipin and methyl-β-cyclodextrin. Whether TGR5-mediated transactivation of the EGFR causes EGFR endocytosis and down-regulation requires further investigation.

Implications for the Functional Effects of TGR5 Agonists—TGR5 has been implicated in several important biological processes, including the control of energy balance (11), insulin and glucose homeostasis (12, 13), inflammation (4, 9, 10, 18), bile formation and secretion (14, 15, 17, 62), intestinal motility and secretion (19, 20), and BA-evoked itch and analgesia (21). The circulating levels of BAs normally wax and wane during feeding and fasting, and during cholestatic diseases, cells would be continuously exposed to high levels of BAs. Our results suggest that, in contrast to many other GPCRs that desensitize and traffic to endosomes soon after activation, activated TGR5 is retained in plasma membrane lipid rafts, from where it can transmit sustained signals. Thus, the mechanisms that control TGR5 signaling in the short term are presently unknown, and whether long-term exposure to agonists regulates TGR5 at the transcriptional level remains to be determined.

TGR5 has emerged as a promising target for metabolic, inflammatory, and digestive diseases, where agonists may promote energy expenditure and insulin release, dampen inflammation, and promote colon transit (4). Therefore, it will be important to determine how these agonists regulate TGR5. Our results show that one synthetic agonist, CCDC, can induce association of TGR5 with β-arrestin2 and GRK2, in contrast to the actions of endogenous BAs. Although CCDC could be a biased agonist of TGR5, the ability of this agonist to stimulate β-arrestin2 and GRK2 recruitment could simply reflect its increased potency. Whether other TGR5 agonists differentially affect TGR5 signaling and trafficking and also function as biased agonists remains to be determined. TGR5 has recently been implicated in the pruritus that is associated with cholestatic disease, raising the possibility that receptor antagonists could provide a novel treatment for itch (21). However, the effects of antagonists on TGR5 signaling are unexplored. In summary, the BA receptor TGR5 transmits signals from plasma membrane lipid rafts that are sustained, β-arrestin-independent, and depend on interaction with the EGFR.

Acknowledgments—We thank Drs. Michael Crouch and Ron Osmond of TGR Biosciences, Adelaide for the AlphaScreen SureFire kits.

REFERENCES

1. Bajor, A., Gillberg, P. G., and Abrahamsson, H. (2010) Bile acids. Short and long term effects in the intestine. Scand. J. Gastroenterol. 45, 645–664
2. Hofmann, A. F., and Hagey, L. R. (2008) Bile acids. Chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol. Life Sci. 65, 2461–2483
3. Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., and Staels, B. (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89, 147–191
4. Pols, T. W., Noriega, L. G., Nomura, M., Auwerx, J., and Schoonjans, K. (2013) The bile acid membrane receptor TGR5. A valuable metabolic target. Dig. Dis. 29, 37–44
5. Claudel, T., Staels, B., and Kuipers, F. (2005) The Farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25, 2020–2030
6. Wang, H., Chen, J., Hollister, K., Sowers, L. C., and Forman, B. M. (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/Bar. Mol. Cell 3, 543–553
7. Staudinger, J. L., Goodwin, B., Jones, S. A., Hawkins-Brown, D., Mackenzie, K. I., LaTour, A., Liu, Y., Klaassen, C. D., Brown, K. K., Reinhard, J., Willson, T. M., Koller, B. H., and Kliewer, S. A. (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 98, 3369–3374
8. Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler, M. R., and Mangelsdorf, D. J. (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313–1316
9. Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., Hinuma, S., Fujisawa, Y., and Fujino, M. (2003) A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435–9440
10. Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H.
Sugiyama, E., Nakamura, T., Itadani, H., and Tanaka, K. (2002) Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714–719

Watanabe, M., Houten, S. M., Mataka, C., Christofollole, M. A., Kim, B. W., Sato, H., Messaddeq, N., Hanrey, J. W., Ezaki, O., Kodama, T., Schoonjans, K., Bianco, A. C., and Auwerx, J. (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484–489

Katsumai, S., Hirasawa, A., and Tsujimoto, G. (2005) Bile acids promote glucon-like peptide-1 secretion through TGR5 in a murine enterocyte-like cell line STC-1. Biochem. Biophys. Res. Commun. 329, 386–390

Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiariulo, A., Yamamoto, H., Mataka, C., Pruzański, M., Pelliccieri, R., Auwerx, J., and Schoonjans, K. (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167–177

Keitel, V., Cupisti, K., Ullmer, C., Knoefel, W. T., Kubitz, R., and Häussinger, D. (2009) The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50, 861–870

Lavoie, B., Balembo, O. B., Godfrey, C., Watson, C. A., Vassileva, G., Corvera, C. U., Nelson, M. T., and Mawe, G. M. (2010) Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPRBAR1 receptors and activation of KATP channels. J. Physiol. 588, 3295–3305

Keitel, V., and Häussinger, D. (2011) TGR5 in the biliary tree. Dig. Dis. 29, 45–47

Maruyama, T., Tanaka, K., Suzuki, J., Miyoshi, H., Harada, N., Nakamura, T., Miyamoto, Y., Kanatani, A., and Tamaï, Y. (2006) Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-BAR) in mice. J. Endocrinol. 191, 197–205

Wang, Y. D., Chen, W. D., Yu, D., Forman, B. M., and Huang, W. (2011) The G protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ-light chain enhancer of activated B cells (NF-κB) in mice. Hepatology 54, 1421–1432

Alemi, F., Poole, D. P., Chiu, J., Schoonjans, K., Cattaruzza, F., Grider, J. R., Bunnnett, N. W., and Corvera, C. U. (2013) The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144, 145–154

Poole, D. P., Godfrey, C., Cattaruzza, F., Cottrell, G. S., Kirkland, J. G., Pelayo, J. C., Bunnett, N. W., and Corvera, C. U. (2010) Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastro. Motil. 22, 814–825, e227–e218

Alemi, F., Kwon, E., Poole, D. P., Lieu, T., Lyo, V., Cattaruzza, F., Cevikbas, F., Steinhoff, M., Nassini, R., Materazzi, S., Guerrero-Alba, R., Valdez-Segura, C. U., Nelson, M. T., and Mawe, G. M. (2010) Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPRBAR1 receptors and activation of KATP channels. J. Physiol. 588, 3295–3305

Kocan, M., Dalrymple, M. B., Seber, R. M., Feldman, B. J., and Pfleger, K. D. (2010) Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and β-arrestins. Front. Endocrinol. 1, 12

Savage, E. E., Wootten, D., Christopoulos, A., Sexton, P. M., and Furness, S. G. (2013) A simple method to generate stable cell lines for the analysis of transient protein-protein interactions. Biotechniques 54, 217–221

Lan, T. H., Liu, Q., Li, C., Wu, G., and Lambert, N. A. (2012) Sensitive and high resolution localization and tracking of membrane proteins in live cells with BRET. Traffic 13, 1450–1456

Galés, C., Rebois, R. V., Hogue, M., Trieu, P., Breit, A., Hébert, T. E., and Bouvier, M. (2005) Real-time monitoring of receptor and G-protein interactions in living cells. Nat. Methods 2, 177–184

Wachten, S., Masada, N., Aylng, L. J., Ciruela, A., Nikolaev, V. O., Lohse, M. I., and Cooper, D. M. (2010) Distinct pools of CAMP centre on different isoforms of adenylyl cyclase in pituitary-derived GH3B6 cells. J. Cell. Sci. 123, 95–106

Hasdemir, B., Bunnnett, N. W., and Cottrell, G. S. (2007) Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) mediates post-endocytic trafficking of protease-activated receptor 2 and calcitonin receptor-like receptor-like receptors. J. Biol. Chem. 282, 29646–29657

Jiang, I. L., Collins, J., Davis, R., Lin, K. M., DeCamp, D., Roach, T., Hsu, R., Reves, R. A., Ross, E. M., Taussig, R., Fraser, I., and Sternweis, P. C. (2007) Use of a CAMP BRET sensor to characterize a novel regulation of cAMP by the sphenolosin 1-phosphatase/G13 pathway. J. Biol. Chem. 282, 10576–10584

Halls, M. L., and Cooper, D. M. (2010). Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, β-arrestin 2, PDE4D3 complex. EMBO J. 29, 2772–2787

Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to Image. 25 years of image analysis. Nat. Methods 9, 671–675

Kocan, M., See, H. B., Sampaio, N. G., Eidne, K. A., Feldman, B. J., and Pfleger, K. D. (2009) Agonist-independent interactions between β-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. Mol. Endocrinol. 23, 559–571

Kocan, M., See, H. B., Seber, R. M., Eidne, K. A., and Pfleger, K. D. (2008) Demonstration of improvements to the bioluminescence resonance energy transfer (BRET) technology for the monitoring of G protein-coupled receptors in live cells. J. Biomol. Screen. 13, 888–898

Merchant, J. F., Salahpour, A., Angers, S., Breit, A., and Bouvier, M. (2002) Quantitative assessment of β-1- and β-2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J. Biol. Chem. 277, 44925–44931

Sato, H., Genet, C., and Insel, P. A. (2008) Novel potent and selective bile acid derivatives as TGR5 agonists. Biological screening, structure-activity relationships, and molecular modeling studies. J. Med. Chem. 51, 1831–1841

Evans, K. A., Budzik, B. W., Ross, S. A., Wisnoski, D. D., Jin, J., Rivero, R. A., Vimal, M., Szewczyk, G. R., Jayawickreme, C., Moncol, D. L., Rimm, J. E., Armour, S. L., Weaver, S. P., Griffin, R. J., Tadepalli, S. M., Jeune, M. R., Shearer, T. W., Chen, Z. B., Chen, L., Anderson, D. L., Becherer, J. D., De Los Frailes, M., and Colilla, F. J. (2009) Discovery of 3-aryl-4-isoxazolocarboxamides as TGR5 receptor agonists. J. Med. Chem. 52, 7962–7965

Jacob, C., Cottrell, G. S., Gehringer, D., Schmidlin, F., Grady, E. F., and Bunnnett, N. W. (2005) c-Cbl mediates ubiquitination, degradation, and down-regulation of human protease-activated receptor 2. J. Biol. Chem. 280, 16076–16087

Kocan, M., Dalrymple, M. B., Seber, R. M., Feldman, B. J., and Pfleger, K. D. (2010) Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and β-arrestins. Front. Endocrinol. 1, 12
(2012) Neurotensin-induced proinflammatory signaling in human colonocytes is regulated by β-arrestins and endothelin-converting enzyme-1-dependent endocytosis and resensitization of neurotensin receptor 1. *J. Biol. Chem.* **287**, 15066–15075

46. Kelly, E., Bailey, C. P., and Henderson, G. (2008) Agonist-selective mechanisms of GPCR desensitization. *Br. J. Pharmacol.* **153**, S379–388

47. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., and Ullrich, A. (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. *Nature* **402**, 884–888

48. DeFea, K. A., Zalevsky, J., Thoma, M. S., Déry, O., Mullins, R. D., and Bunnett, N. W. (2000) β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. *J. Cell Biol.* **148**, 1267–1281

49. Maudsley, S., Pierce, K. L., Zamah, A. M., Miller, W. E., Ahn, S., Daaka, Y., Lefkowitz, R. J., and Luttrell, L. M. (2000) The (2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. *J. Biol. Chem.* **275**, 9572–9580

50. Olivares-Reyes, J. A., Shah, B. H., Hernández-Aranda, J., García-Caballero, A., Farshori, M. P., García-Sáinz, J. A., and Catt, K. J. (2005) Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptor. *Mol. Pharmacol.* **68**, 356–364

51. Yin, X., Li, B., Chen, H., and Catt, K. J. (2008) Differential signaling pathways in angiotensin II- and epidermal growth factor-stimulated hepatic C9 cells. *Mol. Pharmacol.* **74**, 1223–1233

52. Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., and Caron, M. G. (2001) Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-β-arrestin complexes after receptor endocytosis. *J. Biol. Chem.* **276**, 19452–19460

53. Oakley, R. H., Laporte, S. A., Holt, J. A., Caron, M. G., and Barak, L. S. (2000) Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. *J. Biol. Chem.* **275**, 17201–17210

54. Schmidlin, F., Déry, O., Bunnett, N. W., and Grady, E. F. (2002) Heterologous regulation of trafficking and signaling of G protein-coupled receptors. β-Arrestin-dependent interactions between neurokinin receptors. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 3324–3329

55. Ramachandran, R., Mihara, K., Chung, H., Renaux, B., Lau, C. S., Muruve, D. A., DeFea, K. A., Bouvier, M., and Hollenberg, M. D. (2011) Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). *J. Biol. Chem.* **286**, 24638–24648

56. Blom, N., Gammeltoft, S., and Brunak, S. (1999) Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. *J. Mol. Biol.* **294**, 1351–1362

57. Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., and Bohn, L. M. (2007) An opioid agonist that does not induce µ-opioid receptor-arrestin interactions or receptor internalization. *Mol. Pharmacol.* **71**, 549–557

58. Haberstock-Debic, H., Kim, K. A., Yu, Y. J., and von Zastrow, M. (2005) Morphine promotes rapid, arrestin-dependent endocytosis of µ-opioid receptors in striatal neurons. *J. Neurosci.* **25**, 7847–7857

59. Keith, D. E., Anton, B., Murray, S. R., Zaki, P. A., Chu, P. C., Lissin, D. V., Monteillet-Agius, G., Stewart, P. L., Evans, C. J., and von Zastrow, M. (1998) µ-Opioid receptor internalization. Opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. *Mol. Pharmacol.* **53**, 377–384

60. Sternini, C., Spann, M., Anton, B., Keith, D. E., Jr., Bunnett, N. W., von Zastrow, M., Evans, C., and Brecha, N. C. (1996) Agonist-selective endocytosis of µ opioid receptor by neurons in vivo. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 9241–9246

61. Whistler, J. L., and von Zastrow, M. (1998) Morphine-activated opioid receptors elude desensitization by β-arrestin. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 9914–9919

62. Li, T., Holmstrom, S. R., Kir, S., Umetani, M., Schmidt, D. R., Kliwer, S. A., and Mangelsdorf, D. J. (2011) The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. *Mol. Endocrinol.* **25**, 1066–1071